About the Lab




  • "Mad Cow Girl; Twisted Prion" performed by The Crested Hens

Sim Lab: Publications


Lau D, Cooper R, Chen J, Sim VL, McCombe JA, Tyrrell GJ, Bhargava R, Ada B, Chapman E, Croxen, MA, Garady C, Antonation K, van Landeghem FKH, Ip S, Saxinger L. Mycobacterium chimaera encephalitis post-cardiac surgery: A new syndrome. Clinical Infectious Diseases. In Press.

Gushue D, Herbst A, Sim V, McKenzie D, Aiken, JM. 14-3-3 and enolase abundances in the CSF of Prion diseased rats. Prion. 2018 Sep 12:1-8. doi: 10.1080/19336896.2018.1513317. 2018.

Norman G, Campeau J, Sim VL. High dose and delayed treatment with bile acids ineffective in RML prion-infected mice. Antimicrob Agents Chemother. 62(8). 2018 May 21. pii: AAC.00222-18. doi: 10.1128/AAC.00222-18. 2018.

Foroutanpay BV, Kumar J, Kang SG, Danaei N, Westaway D, Sim VL, Kar S. The effects of N-terminal mutations on beta-amyloid peptide aggregation and toxicity. Neuroscience. 20(379):177-188. doi: 10.1016/j.neuroscience.2018.03.014. 2018.

Gupta AN, Neupane K, Rezajooei N, Cortez L, Sim V, Woodside MT. Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion protein. Nat Commun. 7:12058. 10.1038/ncomms12058. 2016.

Mostofi E, Schievink WI, Sim VL. Dural Reduction Surgery: A Treatment Option for Frontotemporal Brain Sagging Syndrome. Can J of Neuro Sci. 43:593-5. 2016.

Kang S-G, Kim C, Cortez LM, Yang J, Garza MC, Wille H, Sim VL, Westaway D, McKenzie D, Aiken J. Toll-Like Receptor-Mediated Immune Response Inhibits Prion Propagation. Glia. doi:10.1002/ glia.22973. 2016.

Wolf H, Hossinger A, Fehlinger A, Buettner S, Sim VL, McKenzie D, Vorberg I. Deposition pattern and subcellular distribution of disease-associated prion protein in cerebellar organotypic slice cultures infected with scrapie. Front Neurosci. 9:410. 10.3389/fnins.2015.00410. 2015.

Kumar J, Namsechi R, and Sim VL. Structure-based peptide design to modulate amyloid beta aggregation and reduce cytotoxicity. PLoS ONE. 10(6):e0129087. 2015.

Cortez LM, Campeau J, Norman G, Kalayil M, Van der Merwe J, McKenzie D, and Sim VL. Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease. J Virol. pii: JVI.01165-15. 2015.

Cortez LM and Sim VL. The therapeutic potential of chemical chaperones in protein folding diseases. Prion. 8(2): pii: 28938. 2014.

Kumar J and Sim VL. D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. Prion. 8(1): 119-24. 2014.

Walsh P, Vanderlee G, Yau J, Campeau J, Sim VL, Yip CM, and Sharpe S. The mechanism of membrane disruption by cytotoxic amyloid oligomers formed by PrP(106-126) is dependent on bilayer composition. J. Biol. Chem. Epub 2014 Feb 19.

Campeau JL, Wu G, Bell JR, Rasmussen J, and Sim VL. Loss of dendritic spines in prion-infected organotypic mouse cerebellar cultures. PLoS ONE. 8(12): e81776. 2013.

Herbst A, Banser P, Velasquez CD, Mays CE, Sim VL, Westaway D, Aiken J, and McKenzie D. Infectious Prions Accumulate to High Levels in Non Proliferative C2C12 Myotubes. PLoS Pathog. 9(11): e1003755. 2013.

Cortez LM and Sim VL. Implications of Prion Polymorphisms. Prion. 7(4):7(4):276-279. 2013.

Sim VL. Prion Diseases, in: A. Jackson, (Ed.), Viral Infections of the Human Nervous System. 371-401. 2013.

Cortez LM , Kumar J , Renault L , Young HS , and Sim VL. Mouse prion protein polymorphism 108F/189V affects the kinetics of fibril formation and the response to seeding; evidence for a two step nucleation polymerization mechanism. J. Biol. Chem. 288(7):4772-81. 2013.

Barton KA, Sim VL, Hughson AG, and Caughey B. Analysis of Prions by Field-Flow Fractionation, in: S.K.R. Williams and K.D. Caldwell, (Eds.), Field-Flow Fractionation in Biopolymer Analysis. 139-149. 2012.

Sim VL. Prion Disease: Chemotherapeutic Strategies. Infect. Disord. Drug Targets. 12:144-160. 2012.

Torres-Bugeau CM, Avila CL, Raisman-Vozari R, Papy-Garcia D, Itri R, Barbosa LRS, Cortez L, Sim VL, and Chehin RN. Characterization of Heparin-induced Glyceraldehyde-3-phosphate Dehydrogenase Early Amyloid-like Oligomers and Their Implication on Alpha-Synuclein Aggregation. J. Biol. Chem. 287(4):2398-409. 2012.

Caughey B, Sim VL, Taubner L, Wilham JM, Orrú C, Christensen LB, Barton KA, Raymond GJ, Raymond LD, and Hughson AG. Prion biochemistry, detection & therapeutics, in: V. St. Georgiev, (Ed.), National Institute of Allergy and Infectious Diseases, NIH: Volume 3, Intramural Research. Infectious Disease, 2010, Volume 3, Part 10, 299-303. 2010.

Sim VL and Caughey B. Prion disease therapy: trials and tribulations, in: M. Ramirez-Alvarado, J.W. Kelly, and C.M. Dobson, (Eds.), Protein Misfolding Diseases: Current and Emerging Principles and Therapies. 259-303. 2010.

Sim VL and Caughey B. Recent advances in prion chemotherapeutics. Infect. Disord. Drug Targets. 9:81-91. 2009.

Sim VL and Caughey B. Ultrastructures and strain comparison of under-glycosylated scrapie prion fibrils. Neurobiol. Aging. 30(12):2031-42. 2009.

Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, Priola SA, and Caughey B. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nature Methods. 4(8):645-650. 2007.

Tahiri-Alaoui A, Sim VL, Caughey B, and James W. Molecular heterosis of prion protein beta oligomers: A potential mechanism of human resistance to disease. J. Biol. Chem. 281(45):34171-34178. 2006.

Atarashi R, Sim VL, Nishida N, Caughey B, and Katamine S. Prion strain-dependent differences in conversion of mutant prion proteins in cell culture. J. Virol. 80:7854-7862. 2006.

Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, and Caughey B. The most infectious prion protein particles. Nature. 437:257-261. 2005.

Stay tuned for more coming to a journal near you (hopefully!)

Last updated: 2019-05-31